Katie Couric, Mark McClellan, and Ellen Sigal Huffington Post Op-Ed on 21st Century Cures

Katie Couric, Mark McClellan and Ellen Sigal call for support for the 21st Century Cures Act.

Read More

2014 Conference on Clinical Cancer Research

Friends of Cancer Research and the Engelberg Center for Health Care Reform at Brookings co-hosted discussions on critical issues in cancer care.

Read More

Accelerating Science and Technology

Friends of Cancer Research is our country's leading voice in advocating for policies and solutions that will get treatments to patients in the safest and quickest way posible.

Read More

New collaborative clinical trial launches

Researchers, drug developers, and patient advocates share their thoughts about Lung-MAP

Read More

Breakthrough Therapies In Action

The FDA's Breakthrough Therapy program continues to accelerate the development and approval of groundbreaking new therapies.

Read More

Download the 2014 Annual Report

Friends of Cancer Research's 2014 Annual Report is now available for download.

Read More

Friends Hosts Breakthrough Briefing

Patients, drug developers, and regulators discussed Breakthrough Therapy's progress at our May briefing

Read More

Breakthrough Designations

View More

Cabozantinib - (Exelixis)

for the treatment of renal cell carcinoma (RCC) in patients who have received one prior therapy


Azedra - (Progenics)

for the treatment of patients with malignant pheochromocytoma or paraganglioma)


Lenvima - (Eisai)

for the treatment of advanced and/or metastatic renal cell carcinoma